NCT01834404View on ClinicalTrials.gov

Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Obesity
Interventions
DRUG

Phentermine-Topiramate ER

The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.

DRUG

Placebo

Placebo pills matched the study drug in appearance for the 2 dose levels.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT01834404 - Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients | Biotech Hunter | Biotech Hunter